129 related articles for article (PubMed ID: 37757453)
1. Correction to: Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
Neuro Oncol; 2023 Nov; 25(11):2105. PubMed ID: 37757453
[No Abstract] [Full Text] [Related]
2. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
Liu H; Xu C; Diplas BH; Brown A; Strickland LM; Yao H; Ling J; McLendon RE; Keir ST; Ashley DM; He Y; Waitkus MS
Neuro Oncol; 2023 Sep; 25(9):1563-1575. PubMed ID: 36689342
[TBL] [Abstract][Full Text] [Related]
3. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM
Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668
[TBL] [Abstract][Full Text] [Related]
4. Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma.
Hung NA; Eiholzer RA; Kirs S; Zhou J; Ward-Hartstonge K; Wiles AK; Frampton CM; Taha A; Royds JA; Slatter TL
Mod Pathol; 2016 Mar; 29(3):212-26. PubMed ID: 26769142
[TBL] [Abstract][Full Text] [Related]
5. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
6. Alternative lengthening of telomeres in cancer stem cells in vivo.
Bojovic B; Booth RE; Jin Y; Zhou X; Crowe DL
Oncogene; 2015 Jan; 34(5):611-20. PubMed ID: 24531712
[TBL] [Abstract][Full Text] [Related]
7. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
[TBL] [Abstract][Full Text] [Related]
8. Effect of silencing key proteins in telomerase mechanism and alternative lengthening of telomeres mechanism in laryngeal cancer cells.
Xu Y; Wang X; Chen SM; Chen C; Wang Y; Xiao BK; Tao ZZ
Am J Otolaryngol; 2016; 37(6):552-558. PubMed ID: 27726944
[TBL] [Abstract][Full Text] [Related]
9. Alternative Lengthening of Telomeres in the Budding Yeast
Cohn M; Andersson AK; Mateo RQ; Möller MC
G3 (Bethesda); 2019 Oct; 9(10):3345-3358. PubMed ID: 31427453
[TBL] [Abstract][Full Text] [Related]
10. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
Grobelny JV; Kulp-McEliece M; Broccoli D
Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
[TBL] [Abstract][Full Text] [Related]
11. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
De Vitis M; Berardinelli F; Sgura A
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
[TBL] [Abstract][Full Text] [Related]
12. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme.
Hakin-Smith V; Jellinek DA; Levy D; Carroll T; Teo M; Timperley WR; McKay MJ; Reddel RR; Royds JA
Lancet; 2003 Mar; 361(9360):836-8. PubMed ID: 12642053
[TBL] [Abstract][Full Text] [Related]
13. CSB cooperates with SMARCAL1 to maintain telomere stability in ALT cells.
Feng E; Batenburg NL; Walker JR; Ho A; Mitchell TRH; Qin J; Zhu XD
J Cell Sci; 2020 Feb; 133(4):. PubMed ID: 31974116
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells.
Perrem K; Colgin LM; Neumann AA; Yeager TR; Reddel RR
Mol Cell Biol; 2001 Jun; 21(12):3862-75. PubMed ID: 11359895
[TBL] [Abstract][Full Text] [Related]
15. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.
Lee JC; Jeng YM; Liau JY; Tsai JH; Hsu HH; Yang CY
Mod Pathol; 2015 Aug; 28(8):1064-73. PubMed ID: 26022452
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Analysis of Alternative Lengthening of Telomere Activity.
Sung JY; Lim HW; Joung JG; Park WY
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32784588
[TBL] [Abstract][Full Text] [Related]
17. SMARCAL1 maintains telomere integrity during DNA replication.
Poole LA; Zhao R; Glick GG; Lovejoy CA; Eischen CM; Cortez D
Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14864-9. PubMed ID: 26578802
[TBL] [Abstract][Full Text] [Related]
18. The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit.
Bryan TM; Marusic L; Bacchetti S; Namba M; Reddel RR
Hum Mol Genet; 1997 Jun; 6(6):921-6. PubMed ID: 9175740
[TBL] [Abstract][Full Text] [Related]
19. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.
Grandin N; Pereira B; Cohen C; Billard P; Dehais C; Carpentier C; Idbaih A; Bielle F; Ducray F; Figarella-Branger D; Delattre JY; Sanson M; Lomonte P; Poncet D; Verrelle P; Charbonneau M;
Acta Neuropathol Commun; 2019 Nov; 7(1):175. PubMed ID: 31706351
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of telomerase induces alternative lengthening of telomeres during human esophageal carcinogenesis.
Queisser A; Heeg S; Thaler M; von Werder A; Opitz OG
Cancer Genet; 2013 Nov; 206(11):374-86. PubMed ID: 24331919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]